Literature DB >> 9086517

Maternal serum screening for fetal genetic disorders.

H L Ross1, S Elias.   

Abstract

Maternal serum analyte screening is an integral component of contemporary antenatal care. Based on elevated MSAFP levels, 85% to 90% of NTDs (e.g., anencephaly or spina bifida) can be detected. Using a combination of serum analytes (e.g., MSAFP, hCG, UE3) 55% to 60% of fetal Down's syndrome can be detected. Future strategies for Down's syndrome screening may include the use of new markers such as dimeric inhibin-A and urinary beta-core fragment of hCG, as well as first-trimester screening, particularly with PAPP-A and free beta-hCG.

Entities:  

Mesh：

Substances：

Year:  1997        PMID： 9086517     DOI： 10.1016/s0889-8545(05)70288-6

Source DB:  PubMed          Journal:  Obstet Gynecol Clin North Am        ISSN： 0889-8545            Impact factor:   2.844


  9 in total

1.  Distress associated with prenatal screening for fetal abnormality.

Authors:  Marci Lobel; Lynette Dias; Bruce A Meyer
Journal:  J Behav Med       Date:  2005-02

Review 2.  First trimester ultrasound tests alone or in combination with first trimester serum tests for Down's syndrome screening.

Authors:  S Kate Alldred; Yemisi Takwoingi; Boliang Guo; Mary Pennant; Jonathan J Deeks; James P Neilson; Zarko Alfirevic
Journal:  Cochrane Database Syst Rev       Date:  2017-03-15

Review 3.  First and second trimester serum tests with and without first trimester ultrasound tests for Down's syndrome screening.

Authors:  S Kate Alldred; Yemisi Takwoingi; Boliang Guo; Mary Pennant; Jonathan J Deeks; James P Neilson; Zarko Alfirevic
Journal:  Cochrane Database Syst Rev       Date:  2017-03-15

Review 4.  Second trimester serum tests for Down's Syndrome screening.

Authors:  S Kate Alldred; Jonathan J Deeks; Boliang Guo; James P Neilson; Zarko Alfirevic
Journal:  Cochrane Database Syst Rev       Date:  2012-06-13

5.  Differences between human and mouse alpha-fetoprotein expression during early development.

Authors:  E A Jones; M Clement-Jones; O F James; D I Wilson
Journal:  J Anat       Date:  2001-05       Impact factor: 2.610

6.  Characterization of alpha-fetoprotein levels in three dolphin species: development of sensitive immunoassays for analysis of the pregnancy-associated variations.

Authors:  Yuka Morita; Naoshi Hiramatsu; Toshiaki Fujita; Haruna Amano; Etsuko Katsumata; Kazutoshi Arai; Toshihide Iwasaki; Takashi Todo; Akihiko Hara
Journal:  J Reprod Dev       Date:  2013-05-08       Impact factor: 2.214

Review 7.  First trimester serum tests for Down's syndrome screening.

Authors:  S Kate Alldred; Yemisi Takwoingi; Boliang Guo; Mary Pennant; Jonathan J Deeks; James P Neilson; Zarko Alfirevic
Journal:  Cochrane Database Syst Rev       Date:  2015-11-30

Review 8.  Urine tests for Down's syndrome screening.

Authors:  S Kate Alldred; Boliang Guo; Yemisi Takwoingi; Mary Pennant; Susanna Wisniewski; Jonathan J Deeks; James P Neilson; Zarko Alfirevic
Journal:  Cochrane Database Syst Rev       Date:  2015-12-10

9.  The C677T methylenetetrahydrofolate reductase variant and third trimester obstetrical complications in women with unexplained elevations of maternal serum alpha-fetoprotein.

Authors:  Natalie K Björklund; Jane A Evans; Cheryl R Greenberg; Lorne E Seargeant; Carol E Schneider; Bernard N Chodirker
Journal:  Reprod Biol Endocrinol       Date:  2004-09-07       Impact factor: 5.211
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.